SE431202B - ANALOGY PROCEDURE FOR PREPARATION OF N-CYANOALKYL-P-HALOGENPHENOXY-ISOBUTYRAMIDES WITH BLOOD FAT CONTENTS - Google Patents

ANALOGY PROCEDURE FOR PREPARATION OF N-CYANOALKYL-P-HALOGENPHENOXY-ISOBUTYRAMIDES WITH BLOOD FAT CONTENTS

Info

Publication number
SE431202B
SE431202B SE7802694A SE7802694A SE431202B SE 431202 B SE431202 B SE 431202B SE 7802694 A SE7802694 A SE 7802694A SE 7802694 A SE7802694 A SE 7802694A SE 431202 B SE431202 B SE 431202B
Authority
SE
Sweden
Prior art keywords
preparation
halogenphenoxy
isobutyramides
cyanoalkyl
blood fat
Prior art date
Application number
SE7802694A
Other languages
Swedish (sv)
Other versions
SE7802694L (en
Inventor
A Esanu
Original Assignee
Soc D Etudes Prod Chimique
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Soc D Etudes Prod Chimique filed Critical Soc D Etudes Prod Chimique
Publication of SE7802694L publication Critical patent/SE7802694L/en
Publication of SE431202B publication Critical patent/SE431202B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00Carboxylic acid nitriles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)

Description

7802694-5 CH3 I R __. O-C-CO-NH2 + CH I CH3 basiskt medel 2=CH~(CH2)p-CN CH3 I 0-C-CO-NH- CH -CN , ( 2)n CH3 Uppfinningen beskrives närmare med följande exempel. 7802694-5 CH3 I R __. O-C-CO-NH 2 + CH 1 CH 3 basic agent 2 = CH 2 (CH 2) p -CN CH 3 I O-C-CO-NH-CH-CN, (2) n CH 3 The invention is further described by the following examples.

Exempel 1 N-cyanoetyl-p-klorfenoxi-isobutyramid I en 5 liters reaktor, försedd med uppvärmningsanordning, kylanord- ning och omrörare, framställdes vid 60°C en lösning av 1,220 g (5,71 mol) p~klorfenoxi-isobutyramid i 1,8 liter dioxan. Därefter tillsattes 23 g pulverformigt natriumkarbonat och långsamt (under minuter), under det att temperaturen höllss mellan 60 och 65°C, 394 ml akrylnitril. Reaktionsblandningen omrördes 15 minuter vid samma temperatur och filtrerades därefter under behandling med 60 g kolsvart. 1,6 liter dioxan sattes till filtratet och efter omrör- ning tillsattes lângsamt 10 liter avjoniserat vatten, varefter om- rörning upprätthölls 2 timmar och därefter fick reaktionsblandnin- gen vila 12 timmar. Efter separation av fällningen, tvätt med vat- ten och torkning vid 40°C erhölls 1,380 g av en beige produkt, som efter omkristallisation (isopropanol + vatten) gav 1,001 g (73%-igt utbyte) av en vit kristallin produkt, som smälte vid 71°C.Example 1 N-cyanoethyl-p-chlorophenoxy-isobutyramide In a 5 liter reactor, equipped with a heating device, cooling device and stirrer, a solution of 1.220 g (5.71 mol) of p-chlorophenoxy-isobutyramide was prepared at 60 ° C. , 8 liters of dioxane. Then 23 g of powdered sodium carbonate and 394 ml of acrylonitrile were added slowly (for minutes), while maintaining the temperature between 60 and 65 ° C. The reaction mixture was stirred for 15 minutes at the same temperature and then filtered while treating with 60 g of carbon black. 1.6 liters of dioxane were added to the filtrate and after stirring slowly 10 liters of deionized water were added, after which stirring was maintained for 2 hours and then the reaction mixture was allowed to rest for 12 hours. After separation of the precipitate, washing with water and drying at 40 DEG C., 1.380 g of a beige product were obtained, which after recrystallization (isopropanol + water) gave 1.001 g (73% yield) of a white crystalline product which melted. at 71 ° C.

Produktens analys stämde väl överens med formeln C13H15O2N2Cl.The analysis of the product was in good agreement with the formula C13H15O2N2Cl.

Exempel 2 N-cyanoetyl-p-fluorfenoxi-isobutyramid Förfarandet enligt exempel 1 upprepades, men p-klorfenoxi-isobutyr- amid användes i stället för p-fluorfenoxi-isobutyramid. Utbytet var 64% av en vit kristallin produkt med en smältpunkt av 75°C.Example 2 N-Cyanoethyl-p-fluorophenoxy-isobutyramide The procedure of Example 1 was repeated, but p-chlorophenoxy-isobutyramide was used instead of p-fluorophenoxy-isobutyramide. The yield was 64% of a white crystalline product with a melting point of 75 ° C.

Analysen överensstämde väl med formeln C13H15O2N2F. _ Exempel 3 N-cyanobutyl-p-klorfenoxi-isobutyramid Förfarandet enligt exempel 1 upprepades, men akrylnitril ersattes 7802-694-5 med pentylnitril. En vit kristallin produkt erhölls med ett 77%-igt utbyte och en smältpunkt av 88°C. Analysen överensstämde väl med formeln C15H19N2O2Cl.The analysis was in good agreement with the formula C13H15O2N2F. Example 3 N-Cyanobutyl-p-chlorophenoxy-isobutyramide The procedure of Example 1 was repeated, but acrylonitrile was replaced with pentylnitrile 7802-694-5. A white crystalline product was obtained with a 77% yield and a melting point of 88 ° C. The analysis was in good agreement with the formula C15H19N2O2Cl.

Toxicitet Den akuta toxiciteten bestämdes per os på möss och råttor med vanli- ga metoder. LD50-värdena är resp. 1 g/kg för möss och över 2,4 g/kg för råttor för föreningen enligt exempel 1.Toxicity Acute toxicity was determined per os in mice and rats by standard methods. The LD50 values are resp. 1 g / kg for mice and over 2.4 g / kg for rats for the compound of Example 1.

För föreningarna enligt exemplen 2 och 3 är LDSO-värdena 1,2 g/kg för båda för möss och över 2,5 g/kg för båda för råttor.For the compounds of Examples 2 and 3, the LDSO values are 1.2 g / kg for both for mice and above 2.5 g / kg for both for rats.

Den subaktua toxiciteten för föreningen enligt exempel 1 undersöktes på råttor vid doserna 40, 80 och 160 mg/kg per os, och ingen skill- nad noterades mellan de behandlade djuren och kontrolldjuren.The subactual toxicity of the compound of Example 1 was tested in rats at doses of 40, 80 and 160 mg / kg per os, and no difference was noted between the treated animals and the control animals.

Farmakologi Triton-test Experimentell hyperlipoidemi och hyperkolesterolemi inducerades på råttor av hankön genom íntraperitoneal injektion av triton (dos 5 ml/ kg). Dessa råttor behandlades omedelbart per os antingen med produk- ten enligt exempel 1 eller med 2-(4-klorfenoxi)-2-metyl-propansyra- etylester eller med nikotinsyra (tre grupper om vardera 10 djur) med samma doser. De bästa hypokolesterolemi-aktiviteterna återfanns för föreningen enligt uppfinningen och den första referensföreningen, under det att de bästa hypotriglyceridemi-aktiviteterna återfanns för den andra referensföreningen och föreningen enligt uppfinningen. ëliniska försök patienter behandlades för jämförelsens skull successivt med 2-(4-klorfenoxi)-2-metyl-propansyra-etylester - referensförening - (30 dagar, 2 g/dag) och efter 15 dagar utan behandling med förenin- gen enligt exempel 1 - förening enligt uppfinningen - (30 dagar, 2 g/dag).Pharmacology Triton test Experimental hyperlipoidemia and hypercholesterolemia were induced in male rats by intraperitoneal injection of triton (dose 5 ml / kg). These rats were immediately treated orally either with the product of Example 1 or with 2- (4-chlorophenoxy) -2-methyl-propanoic acid ethyl ester or with nicotinic acid (three groups of 10 animals each) at the same doses. The best hypocholesterolemia activities were found for the compound of the invention and the first reference compound, while the best hypotriglycerideemia activities were found for the second reference compound and the compound of the invention. For clinical comparison, patients were successively treated with 2- (4-chlorophenoxy) -2-methyl-propanoic acid ethyl ester - reference compound - (30 days, 2 g / day) and after 15 days without treatment with the compound of Example 1 - compound of the invention - (30 days, 2 g / day).

Medelvärdena i g/1 för de ursprungliga värdena, slutvärdena cch_ minskning av triglycerider, total kolesterolmängd och total lipid- mängd âterges i följande tabell. 4 7802694-5 Referensförening Förening enl. uppf.The mean values in g / l for the initial values, final values and decrease in triglycerides, total cholesterol and total lipid are given in the following table. 4 7802694-5 Reference association Association acc. opg.

Triglxcerider ursprungligt värde 1,011 (ï 0,090) 1,59 (1 0,155) sintvärae 1,137 (i 0,005) 1,002 (1 0,101) minskning 0,474 (i 0,102) 0,507 (i 0,000) Total mängd kolesterol ursprungligt värde 7 3,31 (1 0,121) 3,17 (3 0,151) sintvärae 2,05 (É 0,170) 2,70 (3 0,169) minskning 0,40 (ï 0,107) 0,47 (i 0,050) Total lipidmängd ursprungligt värde 9,985 (É 0,342) 9,94 (i 0,454) sintvärae 0,775 (i 0,491) 0,367 (i 0,431) minskning p1,210 (3 0,244) 1,572 (i 0,190) Aktiviteten av föreningen enligt uppfinningen förefaller vara den- samma för total mängd kolesterol men mer gynnsamt vad beträffar tri- glycerider och total mängd lipid.Triglycerides original value 1,011 (ï 0,090) 1,59 (1 0,155) sintvärae 1,137 (in 0,005) 1,002 (1 0,101) decrease 0,474 (in 0,102) 0,507 (in 0,,000) Total amount of cholesterol original value 7 3,31 (1 0,121) 3.17 (3 0.151) sintvärae 2.05 (É 0.170) 2.70 (3 0.169) decrease 0.40 (ï 0.107) 0.47 (in 0.050) Total lipid amount initial value 9.985 (É 0.342) 9.94 ( in 0.454) sintvärae 0.775 (in 0.491) 0.367 (in 0.431) decrease p1,210 (3 0.244) 1.572 (in 0.190) The activity of the compound according to the invention appears to be the same for total amount of cholesterol but more favorable in terms of triglycerides and total amount of lipid.

Administreringsform-dos Föreningarna enligt föreliggande uppfinning kan förekomma i vilken lämplig form som helst för human terapi. En lämplig fimmxför oral _ administrering kan t.ex. vara en geletinkapsel som innehåller: förening enligt ett av exemplen 0,500 g kiselsyra D 0,018 g talk 0,042 g 0,560 g Vad beträffar dosen för patienterna kan denna ligga mellan 0,5 och 4 g per dag. ___...Dosage Form Dosage The compounds of the present invention may be in any form suitable for human therapy. A suitable oral administration may be e.g. be a gelatin capsule containing: compound according to one of the examples 0.500 g silicic acid D 0.018 g talc 0.042 g 0.560 g As for the dose for patients, this may be between 0.5 and 4 g per day. ___...

Claims (2)

1. 5 *zeozeøa-s 'Patentkrav Analogiförfarande för framställning av isobutyramid-derivat med den allmänna formeln / \ | R -c-co-NH- cH -c , ( 2)n N -_ CH3. vari R1 betecknar en halogenatom och n betecknar ett heltal1.5 * Zeozeo-s' Claims Analogous process for the preparation of isobutyramide derivatives of the general formula / \ | R -c-co-NH- cH -c, (2) n N -_CH3. wherein R 1 represents a halogen atom and n represents an integer 2. -6, k ä n n e t e c k n a t av att den motsvarande sub- stituerade fenoxi-isobutyramiden med formeln ÉHB ~C~CO-NH I CH 2 3 omsättes i dioxan med N-cyanoalkylenen CH2=CH-(CH2)p-CN, vari p betecknar ett heltal 0-4 i närvaro av ett basiskt medel vid en temperatur mellan 50 och 6500.2. -6, characterized in that the corresponding substituted phenoxy-isobutyramide of the formula EHB-C ~ CO-NH in CH 2 3 is reacted in dioxane with the N-cyanoalkylene CH 2 = CH- (CH2) p-CN, wherein p denotes an integer 0-4 in the presence of a basic agent at a temperature between 50 and 6500.
SE7802694A 1977-03-10 1978-03-09 ANALOGY PROCEDURE FOR PREPARATION OF N-CYANOALKYL-P-HALOGENPHENOXY-ISOBUTYRAMIDES WITH BLOOD FAT CONTENTS SE431202B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB10069/77A GB1557420A (en) 1977-03-10 1977-03-10 Preparation of isobutyramide derivatives

Publications (2)

Publication Number Publication Date
SE7802694L SE7802694L (en) 1978-09-11
SE431202B true SE431202B (en) 1984-01-23

Family

ID=9960874

Family Applications (1)

Application Number Title Priority Date Filing Date
SE7802694A SE431202B (en) 1977-03-10 1978-03-09 ANALOGY PROCEDURE FOR PREPARATION OF N-CYANOALKYL-P-HALOGENPHENOXY-ISOBUTYRAMIDES WITH BLOOD FAT CONTENTS

Country Status (26)

Country Link
JP (1) JPS53112823A (en)
AR (1) AR214560A1 (en)
AT (1) AT352104B (en)
AU (1) AU517807B2 (en)
BE (1) BE864075A (en)
CH (1) CH628321A5 (en)
DE (1) DE2810505C3 (en)
DK (1) DK105078A (en)
EG (1) EG13580A (en)
ES (1) ES467566A1 (en)
FI (1) FI780472A (en)
FR (1) FR2383167A1 (en)
GB (1) GB1557420A (en)
HK (1) HK28880A (en)
IE (1) IE46671B1 (en)
IN (1) IN147801B (en)
LU (1) LU79195A1 (en)
MX (1) MX4826E (en)
MY (1) MY8100067A (en)
NL (1) NL7802024A (en)
NO (1) NO143969C (en)
NZ (1) NZ186388A (en)
OA (1) OA05902A (en)
PT (1) PT67667B (en)
SE (1) SE431202B (en)
ZA (1) ZA78618B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE496032T1 (en) 1999-02-24 2011-02-15 Hoffmann La Roche 4-PHENYLPYRIDINE DERIVATIVES AND THEIR USE AS NK-1 RECEPTOR ANTAGONISTS
TWI280239B (en) 2003-07-15 2007-05-01 Hoffmann La Roche Process for preparation of pyridine derivatives
DK1928427T3 (en) 2005-09-23 2010-03-08 Hoffmann La Roche Hitherto unknown dosage formulation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE734725C (en) * 1940-04-17 1943-04-30 Ig Farbenindustrie Ag Process for the preparation of formylamino-ª ‰ -propionitriles
GB1064252A (en) * 1963-09-19 1967-04-05 Ici Ltd Amides and pharmaceutical compositions containing them
GB1041982A (en) * 1963-09-30 1966-09-07 Boots Pure Drug Co Ltd Herbicidal compounds and compositions

Also Published As

Publication number Publication date
IN147801B (en) 1980-06-28
OA05902A (en) 1981-05-31
PT67667A (en) 1978-03-01
NZ186388A (en) 1979-04-26
HK28880A (en) 1980-05-30
ATA148978A (en) 1979-02-15
MX4826E (en) 1982-10-21
FR2383167A1 (en) 1978-10-06
AR214560A1 (en) 1979-06-29
AU517807B2 (en) 1981-08-27
NO143969B (en) 1981-02-09
JPS5715831B2 (en) 1982-04-01
FI780472A (en) 1978-09-11
AT352104B (en) 1979-09-10
NO143969C (en) 1981-06-03
NO780834L (en) 1978-09-12
ES467566A1 (en) 1978-10-16
MY8100067A (en) 1981-12-31
NL7802024A (en) 1978-09-12
BE864075A (en) 1978-06-16
FR2383167B1 (en) 1980-04-25
SE7802694L (en) 1978-09-11
EG13580A (en) 1981-12-31
AU3345978A (en) 1979-08-30
CH628321A5 (en) 1982-02-26
JPS53112823A (en) 1978-10-02
DK105078A (en) 1978-09-11
ZA78618B (en) 1978-12-27
DE2810505B2 (en) 1979-08-30
IE780483L (en) 1978-09-10
IE46671B1 (en) 1983-08-24
DE2810505C3 (en) 1980-05-08
GB1557420A (en) 1979-12-12
LU79195A1 (en) 1978-06-28
PT67667B (en) 1979-07-20
DE2810505A1 (en) 1978-09-14

Similar Documents

Publication Publication Date Title
AU2018311976B2 (en) Inhibitors of Plasma Kallikrein and uses thereof
DK159264B (en) ANALOGY PROCEDURE FOR PREPARING D- (THREO) -1-ARYL-2-ACYLAMIDO-3-FLUOR-1-PROPANOL COMPOUNDS
SU873872A3 (en) Method of preparing aminopropanol derivatives or their salts
EP0186252A2 (en) Use of thiophene compounds for the manufacture of a medicament against tumours
SE431202B (en) ANALOGY PROCEDURE FOR PREPARATION OF N-CYANOALKYL-P-HALOGENPHENOXY-ISOBUTYRAMIDES WITH BLOOD FAT CONTENTS
JPS6294A (en) Novel glycerophosphoric acid derivative and salt and production thereof
CN105601650B (en) Structure, the preparation and use of diethylenetriamine base Chinese blister beetle acid imide dimer derivate
SU1376943A3 (en) Method of producing derivatives of aminopyridine hydroxide or quaternary salts thereof
US4806568A (en) Gossypol derivatives
WO2022089556A1 (en) C-myc protein inhibitor, preparation method therefor, and use thereof
RU2768824C1 (en) 2-(phenyl(phenylimino)methyl)isoindoline-1,3-dione and method for production thereof
SU820658A3 (en) Method of preparing 1-phenylethanolamine derivatives or their salts
JPS63135378A (en) Butyrolactone derivative, production and use thereof
JPH05213980A (en) Preparation and refining of medicine having antineoplasm action, octadecyl-(-2-(n-methyl- piperidino)-ethyl phosphate, and preparation of the medicine
KR810001697B1 (en) New preparation of isobutyramide derivatives
SU940645A3 (en) Process for producing derivatives of 1,1'-biphenyl-2-ylalkylamine
CN114940694B (en) Steroid compound, preparation method thereof and application thereof in treatment of tumors related to p53 mutation
US2855401A (en) Certain n-(aminophenoxy pentyl) sulfonamide or saccharine compounds and higher homologues
CN116120297B (en) 1, 3-Dicyclopropyl-5-substituted cyclic triphosurea compound and application thereof as iron death inducer
JPS63227570A (en) Isoquinoline derivative
NO126374B (en)
US4443458A (en) Aminocrotonyl 3,5-dinitropyridine useful as adjuncts to radiation therapy
DK156436B (en) ANALOGY PROCEDURE FOR PREPARING 6,6'METHYL-BIS (2,2,4-TRIMETHYL-1,2-DIHYDROQUINOLINE) DERIVATIVES AND CONDENSATION PRODUCTS THEREOF
SU664453A1 (en) -[-(dimethylamino) alkalamino] alkylamides of oximinoacetic acid of thetr salts exhibiting anticurare effect
WO2024098273A1 (en) Anti-influenza virus phosphate ester compound and use thereof